by Machingaidze S, Casas CP, Mburu S, Draghia-Akli R, Mowbray CE, Rosen J, Burrone E, Nemer M, Dzau V. PLOS Global Public Health 2024, 4(8): e0003654. doi: 10.1371/journal.pgph.0003654
Summary: The COVID-19 pandemic exposed the inadequate pipeline of therapeutics for diseases with pandemic potential. We need a sustainable and responsive end-to-end research and development ecosystem that can be mobilised during emergencies to rapidly develop key medical countermeasures, including therapeutics. A recent meeting held at the Wellcome Trust, London marked the beginning of a collective endeavour to reinvigorate the therapeutics pipeline, bringing together stakeholders from across the world who agreed on the need for an independent and inclusive coalition. This global therapeutics’ development coalition aims to facilitate rapid, equitable access to pandemic and endemic therapeutics, and the authors of this opinion piece invite interested stakeholders, developers, researchers, funders, and governments to consider how they might be able to contribute.
